Retatrutide Research: Phase 2 Trials, Mechanism and Recent Studies

The short version

Retatrutide is an investigational drug being tested in large clinical trials. It works by activating three hormone signals — GLP-1, GIP, and glucagon — that together reduce appetite, improve blood-sugar control, and cause the body to burn more energy. In the main Phase 2 study, the highest dose tested caused an average 24% body-weight reduction over 48 weeks, which is larger than anything previously seen in a weight-loss drug trial. It has also been studied in people with type 2 diabetes and fatty liver disease, with strong results in both. The drug is not approved anywhere; the large Phase 3 trials are ongoing. This page walks through the published studies one by one, with citations for every number.

Triple-receptor mechanism: GIP, GLP-1 and glucagon

Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide built on a GIP-based backbone, acylated with a C20 fatty-diacid chain for albumin binding (the chain tethers the peptide to albumin in the bloodstream, slowing clearance and extending its duration of action). Molecular formula C221H342N46O68; molecular weight 4731.33 Da ^[1].

A note on terminology: retatrutide is sometimes called "GLP-3" in popular media. This is a misnomer. There is no GLP-3 receptor. Retatrutide is a GIP/GLP-1/glucagon triple agonist — three distinct receptors, three distinct endogenous hormones. The confusion likely arises from the compound following GLP-1 and dual GIP/GLP-1 agonists in the development sequence.

Cryo-EM structural studies resolved its engagement with GLP-1R, GIPR, and GCGR at 2.68/3.26/2.84 Å respectively. Relative to the endogenous hormones, retatrutide is ~8.9× more potent at GIPR, ~0.3× at GCGR, and ~0.4× at GLP-1R ^[3]. This asymmetric potency profile is the pharmacological design: high GIP agonism augments the weight-loss signal from the GLP-1 arm; partial glucagon agonism drives energy expenditure and hepatic lipid metabolism without the hyperglycemia (high blood sugar) that full glucagon agonism would produce. All three signals converge on downstream cAMP/PKA signaling across the class-B GPCR family ^[3].

Phase 1b first-in-human trial

The first-in-human study (72 adults with type 2 diabetes, HbA1c 7.0-10.5%) evaluated escalating doses over 12 weeks via subcutaneous injection once weekly. Key pharmacokinetic finding: half-life approximately 6 days, supporting once-weekly dosing. The highest-dose group (3/6/9/12 mg stepwise escalation) lost -8.96 kg placebo-adjusted (90% CI -11.16 to -6.75 kg). Daily glucose fell -2.8 mmol/L at 3 mg. Treatment-emergent adverse events occurred in 63%, mostly GI; the safety profile was characterized as acceptable ^[4].

Phase 2 obesity trial: primary efficacy

The landmark obesity Phase 2 RCT (338 adults, BMI ≥30 or 27-<30 with comorbidity, 51.8% men, 48 weeks) randomized participants to 1, 4, 8 or 12 mg subcutaneous once weekly or placebo. Primary endpoint: mean body-weight change at 48 weeks.

Results by dose: -8.7% (1 mg), -17.3% (4 mg), -22.8% (8 mg), -24.2% (12 mg) versus -2.1% placebo. GI adverse events were dose-related: nausea in up to 45% at the highest dose. Discontinuation due to adverse events: 18% at 12 mg versus 2% placebo. Heart-rate increase was dose-dependent, peaking at approximately week 24 ^[1].

For perspective on where -24.2% sits on the incretin landscape, the retatrutide vs tirzepatide comparison page maps the Phase 2 figures side by side. The is retatrutide better than semaglutide page does the same for the GLP-1 comparison.

Phase 2 type 2 diabetes trial

The 281-participant Phase 2 T2D RCT tested doses of 0.5-12 mg once weekly with stepwise escalation over 36 weeks. At 24 weeks, 12 mg reduced HbA1c by -2.02 percentage points versus -0.01 in the placebo group. Body weight fell -16.94% versus -3.00% placebo by week 36. Mild-to-moderate GI adverse events occurred in 35% of the active group. No severe hypoglycemia and no deaths were recorded ^[2]. Participants on background insulin required dose adjustment during the trial, consistent with the mechanism of enhanced insulin secretion.

MASLD substudy: liver-fat outcomes

A Phase 2a substudy enrolled 98 participants with obesity or overweight and MASLD (metabolic dysfunction-associated steatotic liver disease — formerly called NAFLD, non-alcoholic fatty liver disease), confirmed by MRI-PDFF liver-fat fraction ≥10%, without type 2 diabetes. At 24 weeks, relative liver-fat reduction by dose: -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), -82.4% (12 mg) versus +0.3% placebo. At 12 mg, 86% of participants reached normal liver fat below 5%. Reductions were sustained to 48 weeks (-86.0% at 12 mg) ^[5].

Appetite and eating behavior

A 2025 clinical analysis specifically characterized appetite, eating attitudes, and eating behaviors during retatrutide treatment. Reduced appetite and altered food-seeking behavior were documented, consistent with the incretin appetite-suppression mechanism, and with the "food noise" suppression frequently described in community reports ^[12].

Phase 3 program and recent comparative evidence

The TRIUMPH Phase 3 program covers obesity, type 2 diabetes, cardiovascular outcomes, and chronic kidney disease. The TRANSCEND-CKD trial (rationale, design and baseline published 2025) is the dedicated renal-outcomes arm ^[10]. An active-comparator Phase 3 RCT directly comparing retatrutide versus tirzepatide (NCT06662383) is enrolled and running — head-to-head data not yet published ^[8].

A 2025 systematic review and meta-analysis of incretin dual and triple agonists found that polyagonists significantly reduced body weight, waist circumference, HbA1c, and fasting glucose versus placebo; GI adverse events and discontinuation rates were higher than placebo — consistent with Phase 2 findings ^[14]. A 2026 network meta-analysis ranked retatrutide highest for weight and HbA1c reduction versus placebo ^[11]. A 2025 review in the World Journal of Cardiology noted that triple agonists demonstrated the highest achievable weight loss with pharmacotherapy among approved and investigational agents, with cardiometabolic benefit expected if weight-loss effects translate to outcomes trials ^[15].